Nutex Health Management
Management criteria checks 3/4
Nutex Health's CEO is Tom Vo, appointed in Apr 2022, has a tenure of 4.17 years. total yearly compensation is $2.20M, comprised of 45.5% salary and 54.5% bonuses, including company stock and options. directly owns 30.56% of the company’s shares, worth $315.79M. The average tenure of the management team and the board of directors is 4.1 years and 4.2 years respectively.
Key information
Tom Vo
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 45.51% |
| CEO tenure | 4.2yrs |
| CEO ownership | 30.6% |
| Management average tenure | 4.1yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Narrative Update • Jun 04
NUTX: Low EV EBITDA Multiple Will Support Future Upside Potential
Analysts have raised their Nutex Health fair value estimate from $221.67 to $235.50, citing what they describe as a relatively low ~3x EV/EBITDA multiple and limited prior coverage of the stock as key reasons for the higher $235 price target. What's in the News No recent company specific news, periodical coverage, or key developments were identified in the provided sources for Nutex Health.
Narrative Update • May 09
NUTX: Share Repurchases Will Support Future Margins And Upside Potential
Analysts now place Nutex Health's fair value at $175.00, up from $150.00, citing updated assumptions around revenue growth of 5.25%, a profit margin of 21.15%, a discount rate of 7.19% and a forward P/E of 7.95. What's in the News On March 5, 2026, the Board of Directors authorized a share buyback plan for Nutex Health.Narrative Update • Apr 23
NUTX: Share Repurchases Will Support Future Margins And Undervalued Upside
Analysts reaffirm a $150.00 price target for Nutex Health, citing updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a small change in future P/E multiples as key inputs to their valuation work. What's in the News Nutex Health Inc.Narrative Update • Apr 09
NUTX: New Buyback Program Will Support Future Margin Resilience
Analysts have raised their Nutex Health price target to $150.00 as they now factor in slightly stronger revenue growth, a modestly higher profit margin of about 18.6%, and a marginally lower future P/E assumption near 8x. What's in the News From October 1, 2025 to December 31, 2025, Nutex Health repurchased 27,870 shares, about 0.4% of its stock, for US$4.95 million under a previously announced buyback program (Key Developments).Narrative Update • Mar 25
NUTX: Share Repurchases Will Support Future Upside Potential
Analysts have adjusted their price target on Nutex Health from $241.67 to $221.67, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Nutex Health completed a previously announced buyback program, repurchasing 27,870 shares, representing 0.4% of the company, for a total of $4.95 million between October 1, 2025 and December 31, 2025 (Key Developments).Narrative Update • Mar 11
NUTX: New Hospitals And Buybacks Will Support Future Margin Resilience
Analysts have adjusted their price target on Nutex Health to $150 from $220, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Nutex Health Inc.Narrative Update • Feb 25
NUTX: Expanded Hospital Footprint Will Support Future Margin Resilience
Analysts have kept their $220.00 price target for Nutex Health unchanged, citing relatively steady assumptions for the discount rate, long-term revenue growth, profit margin, and future P/E expectations. What's in the News Nutex Health announced the opening of its 26th hospital, Archview ER & Hospital, in a new state, Missouri, expanding its footprint into St. Louis for the first time (Key Developments).Narrative Update • Feb 11
NUTX: Future Margin Resilience Will Outlast Fraud Allegations And Filing Delay
Analysts have maintained their Nutex Health fair value estimate at $220.00. They cite small adjustments to the discount rate, revenue growth, profit margin, and expected future P/E assumptions, rather than any major change in their overall view.Narrative Update • Jan 27
NUTX: Future Margin Strength Will Outweigh Fraud Allegation And Filing Risk
Analysts have kept their price target on Nutex Health steady at US$220.00, citing slightly higher modeled revenue growth, a modestly improved profit margin and a marginally lower forward P/E assumption as key reasons for maintaining their view. What's in the News Short seller Capybara Research published a report alleging that Nutex Health and its founder CEO engaged in fraudulent and unethical business practices, citing interviews with former insiders and partners and claiming a pattern of misconduct over about 10 years (Periodical).Narrative Update • Jan 12
NUTX: Future Margin Strength Will Offset Fraud Allegation Headwinds
Analysts have slightly revised their price target on Nutex Health to US$220, reflecting modestly updated assumptions around revenue, profit margins, and future P/E expectations. What's in the News Capybara Research published a report alleging Nutex Health and its CEO engaged in fraudulent and unethical business practices over a period of about 10 years.Narrative Update • Dec 26
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Analysts have modestly raised their price target on Nutex Health to approximately 220 dollars per share, citing slightly stronger anticipated revenue growth and profit margins. These factors support a marginally lower future price to earnings multiple.Narrative Update • Dec 12
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Narrative Update on Nutex Health Analysts have raised their price target on Nutex Health from 205.00 dollars to 220.00 dollars, reflecting expectations for meaningfully improved profit margins and a more favorable future earnings multiple, despite moderating revenue growth assumptions and a slightly lower discount rate. What's in the News Capybara Research issued a report alleging Nutex Health and its CEO engaged in a long running pattern of fraudulent and unethical business practices, and warned that more physician groups and emergency rooms may sever ties with the company (Capybara Research report).Seeking Alpha • Sep 10
Nutex: Diagnosed With A Case Of Fair Value
Summary Nutex Health shows strong revenue growth and a healthy balance sheet, but recent issues with SEC filings and a short report caused the stock to decline. Growth prospects hinge on the execution of expansion, especially in the IPA segment, which could drive future cash flow at low cost. Competitive pressures, cyclical capex, and significant stock-based compensation limit upside and warrant a deeper margin of safety for investors. At current levels, NUTX is not undervalued; I recommend a Hold rating and would only consider buying below $65 for better risk-reward. Read the full article on Seeking AlphaNew Narrative • May 28
Aging US Population Will Drive Micro-Hospital Expansion Despite Payer Challenges
Expansion in key markets and value-focused care models align Nutex with demographic trends and rising demand for accessible, cost-effective healthcare.Analysis Article • Jan 24
Health Check: How Prudently Does Nutex Health (NASDAQ:NUTX) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Dec 25
Nutex Health Inc. (NASDAQ:NUTX) Might Not Be As Mispriced As It Looks
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...Analysis Article • Aug 12
Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target
The analysts might have been a bit too bullish on Nutex Health Inc. ( NASDAQ:NUTX ), given that the company fell short...Analysis Article • Apr 17
Nutex Health Inc.'s (NASDAQ:NUTX) 30% Cheaper Price Remains In Tune With Revenues
Unfortunately for some shareholders, the Nutex Health Inc. ( NASDAQ:NUTX ) share price has dived 30% in the last thirty...Seeking Alpha • Aug 23
Nutex Health GAAP EPS of -$0.03, revenue of $58.05M
Nutex Health press release (NASDAQ:NUTX): Q2 GAAP EPS of -$0.03. Revenue of $58.05M (-7.6% Y/Y). Adjusted EBITDA of $9.4M. As of June 30, 2022, the company had total assets of $871.8M, including cash and cash equivalents of $47.6M.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$96m |
| Dec 31 2025 | US$2m | US$1m | US$71m |
| Sep 30 2025 | n/a | n/a | US$121m |
| Jun 30 2025 | n/a | n/a | US$56m |
| Mar 31 2025 | n/a | n/a | US$74m |
| Dec 31 2024 | US$662k | US$558k | US$52m |
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$38m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | US$1m | US$1m | -US$46m |
| Sep 30 2023 | n/a | n/a | -US$29m |
| Jun 30 2023 | n/a | n/a | -US$436m |
| Mar 31 2023 | n/a | n/a | -US$451m |
| Dec 31 2022 | US$938k | US$932k | -US$425m |
| Sep 30 2022 | n/a | n/a | -US$396m |
| Jun 30 2022 | n/a | n/a | US$70m |
| Mar 31 2022 | n/a | n/a | US$122m |
| Dec 31 2021 | US$258k | US$251k | US$133m |
| Sep 30 2021 | n/a | n/a | US$159m |
| Dec 31 2020 | US$159k | US$151k | US$106m |
Compensation vs Market: Tom's total compensation ($USD2.20M) is below average for companies of similar size in the US market ($USD3.69M).
Compensation vs Earnings: Tom's compensation has increased by more than 20% in the past year.
CEO
Tom Vo (53 yo)
4.2yrs
Tenure
US$2,197,420
Compensation
Dr. Thomas T. Vo, also known as Tom, M.D., MBA, is Chairman of the Board and Chief Executive Officer of Nutex Health, Inc. from April 1, 2022. Dr. Vo joined the Nutex Health, Inc. in April 1, 2022. He is t...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.2yrs | US$2.20m | 30.56% $ 315.8m | |
| President & Director | 4.2yrs | US$1.71m | 0.11% $ 1.2m | |
| Chief Financial Officer | 4yrs | US$924.21k | 0.12% $ 1.2m | |
| Chief Operating Officer | less than a year | US$392.72k | no data | |
| Chief Medical Officer | 4.2yrs | US$716.59k | 1.2% $ 12.4m | |
| Investor & Public Relations Manager | 1.2yrs | no data | no data | |
| Director of Compliance | 2.9yrs | no data | no data | |
| Director of Marketing | no data | no data | no data | |
| Director of Human Resources | 4.4yrs | no data | no data | |
| Chief Legal Officer & Board Secretary of SEC | 4.2yrs | US$593.32k | 0.034% $ 355.9k | |
| Chief Legal Officer of Healthcare & Board Secretary | no data | US$275.36k | 0.040% $ 414.1k | |
| Director of Treasury | 1.2yrs | no data | no data |
4.1yrs
Average Tenure
54.5yo
Average Age
Experienced Management: NUTX's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.2yrs | US$2.20m | 30.56% $ 315.8m | |
| President & Director | 4.2yrs | US$1.71m | 0.11% $ 1.2m | |
| Independent Director | 2.2yrs | US$268.35k | 0% $ 0 | |
| Independent Director | less than a year | US$152.27k | 0.0022% $ 22.5k | |
| Lead Independent Director | 4.2yrs | US$277.61k | no data | |
| Independent Director | 4.2yrs | US$271.87k | 0.00097% $ 10.0k | |
| Director | 2.2yrs | no data | 0.50% $ 5.2m |
4.2yrs
Average Tenure
65yo
Average Age
Experienced Board: NUTX's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/23 10:20 |
| End of Day Share Price | 2026/06/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nutex Health Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Sutherland | Benchmark Company |
| Eugene Mannheimer | Freedom Capital Markets |
| Benjamin Haynor | Lake Street Capital Markets, LLC |